Using computer simulations to compare pertussis vaccination strategies in Australia.

High levels of notified pertussis in adolescents and adults, persisting severe disease (hospitalization and deaths) in infants despite high childhood immunization coverage, together with the availability of adult-formulated pertussis vaccines, have made alternate strategies for vaccine control of pertussis an important issue in Australia. An age-structured computer simulation model was used to compare the likely effects of adopting different vaccination strategies in Australia on pertussis transmission by age group over a 50 year time period. Epidemiological parameters and vaccination coverage in Australia were estimated from previous pertussis modeling studies and existing data. In the simulations, replacing the pertussis booster at 18 months with a booster dose for adolescents at an age between 12 and 17 years, assuming 80% coverage, led to decreases in pertussis cases of 30% in children of ages 0-23 months (who have the highest complication rates) and of 25% in adolescents, but an increase of 15% in cases in 2-4-year-old children. The simulations did not suggest any shift of pertussis cases into the adult child-bearing years. Varying parameter values in the simulations in a series of sensitivity analyses showed the model predictions to be robust over a plausible range. The results of these simulations suggest that the recent change in the Australian pertussis vaccination schedule, replacing the 18 month dose with a pertussis booster in 15-17-year-old adolescents, is very likely to reduce overall pertussis incidence in Australia without increasing the cost of the current vaccine program.

[1]  S. Long,et al.  Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. , 1990, The Journal of infectious diseases.

[2]  P. Horby,et al.  Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000 This report was written at the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS) by: , 2002 .

[3]  K. Edwards,et al.  Pertussis infection in adults with persistent cough. , 1995, JAMA.

[4]  S. Salmaso,et al.  Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. , 2001, Pediatrics.

[5]  W. Blackwelder,et al.  A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.

[6]  H. Hallander,et al.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. , 1996, The New England journal of medicine.

[7]  M. Granström,et al.  Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. , 1989, Pediatrics.

[8]  W. Edmunds,et al.  Modelling the impact of immunization on the epidemiology of varicella zoster virus , 2000, Epidemiology and Infection.

[9]  H. Hethcote,et al.  An age-structured model for pertussis transmission. , 1997, Mathematical biosciences.

[10]  B. Jalaludin,et al.  A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. , 2000, Vaccine.

[11]  J. Cherry,et al.  Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine , 2002, European Journal of Pediatrics.

[12]  J. Cherry,et al.  A Search for Bordetella pertussis Infection in University Students , 1992 .

[13]  J. Cherry Epidemiological, clinical, and laboratory aspects of pertussis in adults. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Cherry,et al.  Frequency of unrecognized Bordetella pertussis infections in adults. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R M May,et al.  Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes , 1985, Journal of Hygiene.

[16]  M. Kretzschmar,et al.  The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies , 2000, Epidemiology and Infection.

[17]  K. Forsyth,et al.  Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. , 2001, Vaccine.

[18]  P. Horby,et al.  Vaccine-preventable diseases and vaccination coverage in Australia, 1999-2000. , 2002, New South Wales public health bulletin.

[19]  New Vaccination Strategies for Pertussis , 2002 .

[20]  T. Kurashige,et al.  Two primary doses of diphtheria-tetanus-acellular pertussis vaccine induce immunological responses to Bordetella pertussis as strong as those induced by three primary doses. , 1997, Vaccine.

[21]  D Greco,et al.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.

[22]  A. Melegaro,et al.  The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. , 2002, Vaccine.

[23]  B. Jalaludin,et al.  Long day care centre immunisation rates in western Sydney , 1996 .

[24]  M. van Boven,et al.  Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. , 2000, Mathematical biosciences.

[25]  M K Viljanen,et al.  Outcomes of Bordetella pertussis infection in different age groups of an immunized population. , 1994, The Journal of infectious diseases.

[26]  B T Grenfell,et al.  Pertussis in England and Wales: an investigation of transmission dynamics and control by mass vaccination , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[27]  K. Edwards,et al.  Prevalence and incidence of adult pertussis in an urban population. , 1996, JAMA.

[28]  S. Halperin,et al.  Morbidity of pertussis in adolescents and adults. , 2000, The Journal of infectious diseases.

[29]  D. Skowronski,et al.  An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. , 2000, Vaccine.

[30]  S. Cordova,et al.  The outbreak that had to happen: Bordetella pertussis in north-west Western Australia in 1999. , 2000, Communicable diseases intelligence.

[31]  E. L. Miller,et al.  The sero-epidemiology of diphtheria in Western Europe , 2000, Epidemiology and Infection.

[32]  MARGARETA BLENNOW,et al.  Long term serologic follow‐up after pertussis immunization , 1990, The Pediatric infectious disease journal.

[33]  Carlos Castillo-Chavez,et al.  Mathematical approaches for emerging and reemerging infectious diseases , 2002 .

[34]  P. Thomas,et al.  Survey of pertussis morbidity in adults in western Sydney , 2000, The Medical journal of Australia.

[35]  H. Hethcote,et al.  Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. , 1999, Mathematical biosciences.

[36]  D. Earn,et al.  Opposite patterns of synchrony in sympatric disease metapopulations. , 1999, Science.

[37]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[38]  J. A. Hunt,et al.  Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. , 2001, The Journal of infectious diseases.

[39]  M. Granström,et al.  A ten year follow-up after immunization with a two component acellular pertussis vaccine. , 1999, The Pediatric infectious disease journal.

[40]  D. Heymann Control of Communicable Diseases Manual , 2004 .

[41]  J. Deen,et al.  Household contact study of Bordetella pertussis infections. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  P S Schenck,et al.  CONTROL OF COMMUNICABLE DISEASES. , 1914, American journal of public health.

[43]  S. Halperin Pertussis immunization for adolescents: What are we waiting for? , 2001, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[44]  B T Grenfell,et al.  The estimation of age-related rates of infection from case notifications and serological data , 1985, Journal of Hygiene.

[45]  E. Zell,et al.  Epidemiological features of pertussis in the United States, 1980-1989. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  W. Yih,et al.  The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. , 2000, The Journal of infectious diseases.

[47]  M. Brennan,et al.  Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  J. Mezzatesta,et al.  Adult immunization with acellular pertussis vaccine. , 1993, JAMA.